WHO says partners can start talks to buy mpox vaccines before its approval
Adds Gavi comment, paragraphs 9-10
WHO partners such as Gavi and UNICEF can buy mpox vaccines before approval
Bavarian Nordic and KM Biologics vaccines already approved in US and Japan
Gavi prioritizes donated doses, ready to procure once demand is clear
By Jennifer Rigby
LONDON, Aug 23 (Reuters) -The World Health Organization said on Friday its partners such as Gavi and UNICEF can start buying mpox vaccines before they are approved by the U.N. health agency, to get inoculations to Africa faster as the continent battles an escalating outbreak of the virus.
Traditionally, organisations like Gavi, which helps lower-income countries buy vaccines, can only start purchasing shots once they have approval from the WHO. But the rules have been relaxed in this instance to get talks moving, as the WHO's approval is due in a few weeks.
Two vaccines, made by Denmark's Bavarian Nordic BAVA.CO and Japan's KM Biologics, are already approved by regulators around the world, including the U.S. and Japan, and have been in widespread use for mpox since 2022. Around 1.2 million people have had Bavarian Nordic's vaccine in the U.S. alone. The WHO is expected to grant an emergency licence to the shots in September.
Mpox, a viral infection that spreads through close contact and is usually mild but can kill, was declared a public emergency of international concern by the WHO last week after a new offshoot of the virus spread quickly in Democratic Republic of Congo and beyond.
Earlier this month, the WHO asked vaccine manufacturers to submit information so it could accelerate its approval process, and grant an emergency licence by mid-September.
However this week, one of the vaccine manufacturers, Bavarian Nordic, said it needed orders immediately from organisations such as Gavi and the WHO to make more shots this year, raising fears that lower-income countries could miss out or be forced to rely on precarious donations from high-income countries, as happened during the COVID-19 pandemic.
Some donated mpox vaccines are due to arrive in Africa next week, the Africa Centres for Disease Control and Prevention has said. The agency has said 10 million doses are needed.
"While we see the news from WHO as a positive, we are not able to comment on specific negotiations. We will update the market in due time if and when orders materialize," a spokesperson for Bavarian Nordic said.
A spokesperson for Gavi said that getting donated doses to countries, and into vaccination programmes, was the first priority.
"When it comes to procuring vaccines directly, since a public health emergency of international concern was announced last week, we have intensified our efforts, with near-daily contact with manufacturers: we are ready to go as soon as we get a clear picture on demand,” the spokesperson said.
KM Biologics did not immediately respond to requests for comment.
Reporting by Jennifer Rigby, additional reporting by Maggie Fick
Editing by Christina Fincher, Susan Fenton, William Maclean and Rod Nickel
Senaste nytt
Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.
Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.
Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.
